StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > LOI Carr

<< Previous

Bullboard Posts

Next >>

Comment by LithLoveron May 27, 2021 1:14pm

87 Views

Post# 33276383

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:LOI Carr

Didn't CN get like 700 million in a penalty payout. But I hear ya.

Nothing's done until its done. But I look at their participation on the call a couple weeks ago as a pretty positive sign.

brad129 wrote: Example on March 21 CP Rail and southern Pacific announce CP buying them for such and such a share price, how did that work out CN Rail ended up buying them.

<< Previous

Bullboard Posts

Next >>

Investor’s corner: Solving chronic pain in dogs – A significant market opportunity